2025-01-13
ImmuneOnco IMM2510 Combined with Chemotherapy for First-Line NSCLC Treatment Completes Enrollment of First Patient in Phase Ib/II Clinical Trial
On January 13, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco", Stock Code: 01541.HK) announced that the Phase Ib/II clinical trial of its PD-L1xVEGF bispecific antibody IMM2510 combined with chemotherapy for the treatment of first-line non-small cell lung cancer (NSCLC) has completed the enrollment of its first patient. This marks another significant milestone in the rapid clinical advancement of IMM2510.
View more

2024-09-16
ImmuneOnco and Instil Bio Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, IMM2510/SYN-2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
Dallas, Texas, and Shanghai, China, Sep. 16, 2024 – Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541, “ImmuneOnco”) announced today the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in front-line non-small cell lung cancer (NSCLC) and in front-line triple-negative breast cancer (TNBC).
View more
